porno atasehir escort bostanci escort erenkoy escort goztepe escort kadikoy Escort kartal Escort maltepe Escort suadiye Escort uskudar Escort umraniye Escort kartal escort bostanci escort atasehir escort kadikoy escort kurtkoy escort tuzla escort erenkoy escort beykoz escort umraniye escort pendik escort kadikoy escort maltepe escort antalya escort konya escort

Market Research Reports and Industry Reports

Ovarian Cancer [2017]: Bulletin #1

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS



This update bulletin presents key opinion leader (KOL) insights on recent events in the ovarian cancer treatment landscape. Topics covered include; the US approval and launch of Tesaros PARP inhibitor Zejula (niraparib) for the maintenance treatment of recurrent ovarian cancer that is in complete or partial response to platinum-based chemotherapy; the Phase III ARIEL3 trial of Clovis PARP inhibitor Rubraca (rucaparib) meeting its primary endpoint of improved progression-free survival (PFS) in platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer; and the new data from the Phase I/II ECHO-204 trial evaluating Incytes IDO1 inhibitor epacadostat plus Bristol-Myers Squibbs PD-1 inhibitor Opdivo (nivolumab) in multiple solid tumours types, including ovarian cancer, presented at ASCO 2017.





Business Questions:

How do KOLs view the US approval of Tesaros Zejula?
How will Zejula be used in the treatment of ovarian cancer?
How will oncologists choose between the PARP inhibitors, and how is their comparative efficacy viewed, in the platinum-sensitive, maintenance setting?
How do the KOLs interpret the results of the ARIEL3 trial of Clovis Rubraca, and how do they view the overall significance of these data?
Where do KOLs see Rubraca fitting into the ovarian cancer treatment algorithm in the longer term?
How do KOLs view the findings from the ECHO-204 trial of Bristol-Myers Squibbs PD-1 inhibitor Opdivo in combination with Incytes IDO1 inhibitor epacadostat?
How do KOLs view the overall potential for combining an IDO inhibitor with a PD-1 inhibitor in the treatment of ovarian cancer and what could increase the chance of success for such combinations?

Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Size, Status and Forecast 2022

This report studies the global Polycystic Ovarian Syndrome (PCOS) Treatment market, analyzes and researches the Polycystic Ovarian Syndrome (PCOS) Treatment development status and forecast in United States, EU, Japan, China,

USD 3300View Report

Global Polycystic Ovarian Syndrome Treatment Market Size, Status and Forecast 2022

This report studies the global Polycystic Ovarian Syndrome Treatment market, analyzes and researches the Polycystic Ovarian Syndrome Treatment development status and forecast in United States, EU, Japan, China, India and

USD 3300View Report

Breast Cancer [2017]: Bulletin #1

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results

USD 1045View Report

Global Ovarian Cancer Drugs Market Professional Survey Report 2017

This report studies Ovarian Cancer Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions,

USD 3500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 1045
  • Enterprise Wide Licence    USD 2575
$ 1045

Reports Details

Published Date : Jul 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube